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Abstract Introduction: Alzheimer’s disease (AD) is a progressive, neurodegenerative disease.
Many studies proposed an association of the insertion (I)/deletion (D) polymorphism (indel) in
intron 16 of the gene for angiotensin I-converting enzyme (ACE) on chromosome 17q23 with Alz-
heimer’s disease. ACE indel and related haplotypes associated with AD risk have reduced plasma
ACE whereas protective genotypes have elevated ACE.
Object: To investigate whether there is a correlation between polymorphisms of the ACE I/D
locus gene and AD in Egyptian patients and to determine whether there is a difference in ACE
activity in the plasma of clinically diagnosed AD patients.
Methods: Subjects of this study are 84 dementia patients diagnosed as having Alzheimer’s dis-
ease, 45 males and 39 females aged 65 ± 7 years from the Geriatric Department at Ain-Shams Uni-
versity Hospitals and 86 individuals as non dementia controls, 44 males and 42 females aged 63
± 6 years.
All subjects were genotyped for the common insertion/deletion polymorphisms for ACE gene
locus, and ACE plasma activity assay was measured for AD patients.
Results: There was statistically significant difference in the frequency of the ACE insertion/dele-
tion alleles between the cases and controls where the I allele distribution in AD cases and controls
was 74% vs. 15%, and the I/I genotype frequency was 60% vs. 5%, respectively. They both reached
a statistical significance range (I allele frequency: OR = 3.714, 95% CI 1.311–10.523, p< 0.01; I/I
Abbreviations: AD, Alzheimer’s disease; ACE, angiotensin converting
enzyme; I/D, insertion/deletion; Ab, amyloid b; LOAD, late-onset
Alzheimer’s disease
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genotype frequency: OR = 3.18 95% CI 2.33–4.33, p< 0.01). But no significant difference in ACE
plasma level was found between different genotypes in our AD patients.
Conclusions: Our present study supports the hypothesis of implication (I allele) of ACE gene
polymorphism in the development of AD. On the other hand, we did not find significant difference
in plasma ACE activities when compared with different studied genotypes.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.
Several studies show that an insertion/deletion (I/D) poly-
orphism in the ACE gene is associated with increased plasma
evel of ACE. Studies showing association between the I/D
olymorphism and cardiovascular disease risk, and evidence
uggesting cardiovascular risk factors promote AD are consis-
ent with the idea that ACE might play a role in AD via a car-
iovascular mechanism [14].
Angiotensin converting enzyme (ACE) plays a key role in
he renin-angiotensin system (RAS) pathway. The actions of
he RAS have been extensively studied in the periphery, partic-
larly the role of Ang II in hypertension. However, it is now
ecognized that nearly all organs of the body have their own
ocal paracrine-like RAS, with organ-specific actions [15].
he actions of Ang II within the central nervous system are
f increasing interest in the context of Alzheimer’s disease
AD). Ang II inhibits the release of acetylcholine (ACh) and
as a pro-inflammatory effect [16].
A polymorphism in the gene coding for angiotensin I-con-
erting enzyme (ACE) was identified by Rigat et al. in 1990
17]. The polymorphism is due to a 287 bp fragment in the
CE gene in chromosome 17. The fragment is present in the
nsertion (I variant) and absent in the deletion (D variant),
hich results in the three genotypes: Homozygotes II and
D and heterozygotes DI. The genotype accounts for approx-
mately half of the variance in the circulating ACE level and
rom the II to the DD genotype the presence of each D allele
s associated with an additive effect on ACE activity (50%
igher in the DD compared with the II genotype) [18].
The relationship between ACE genotypes, in particular
D, and the occurrence of cardiovascular and renal diseases
as therefore been the focus of several studies in the past dec-
de [19].
In 1999, Kehoe et al. [20], proposed the first study that
eported an association between Alzheimer’s disease and the
nsertion (I)/deletion (D) polymorphism (indel) in intron 16
f the gene for angiotensin I-converting enzyme (ACE), and
he D allele is associated with raised plasma levels of the
nzyme [21]. While Lehmann et al. [22], found that I positives,
hat is, DI and II, were at increased risk of Alzheimer’s disease.
The ACE gene (ACE) has been featured now as one of the
op susceptibility genes for AD [20,22]. According to the meta-
nalysis database of AD candidate genes listed on Alzgene
www.Alzgene.org), ACE indel and related haplotypes associ-
ted with AD risk have reduced plasma ACE whereas protec-
ive genotypes have elevated ACE [23]. Other studies have
bserved reduced ACE activity in CSF from AD patients [16].
Indeed after APOE, the only widely accepted susceptibility
ene for late-onset AD [24], ACE1 is probably the strongest
andidate susceptibility gene for AD. The Ab degradation
ypothesis would explain this on the basis that differences in
CE1 genotype influence ACE levels and activity and
hese, in turn, affect Ab accumulation and toxicity. In most
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Dementia will increase exponentially in coming years, and the
number of patients suffering from dementia is predicted to
double every 20 years to 81.1 million by 2040 in the world
[1]. This increasing prevalence underlines the necessity for
antecedent biomarkers in order to have more accurate diagno-
sis and treatment [2].
Alzheimer’s disease (AD) is the most over diagnosed and
misdiagnosed disorder of mental functioning in older adults.
Part of the problem, is that many other disorders show symp-
toms that resemble those of AD. The crucial difference, how-
ever, is that many of these disorders – unlike AD – may be
stopped, reversed, or cured. Based on these findings, clinical
diagnosis of AD has been referred to as ‘‘a diagnosis by exclu-
sion”, and one that can only be made in the face of clinical
deterioration over time. There is no specific clinical test or find-
ing that is unique to AD. Hence, all disorders that can bring on
similar symptoms must be systematically excluded. The ‘‘clas-
sical” senile plaques and the neurofibrillary tangles seen in an
AD brain at autopsy typically are the only definitive diagnosis
of the disease [3].
Alzheimer’s disease (AD) is a progressive, neurodegenera-
tive disease characterized clinically by gradual loss of memory
and pathologically by neurofibrillary tangles and amyloid pla-
ques in the brain. Currently, the apolipoprotein E e4 allele is
the only broadly recognized genetic risk factor for late-onset
AD (LOAD) in most populations. Much attention has been
focused on the connection between angiotensin I converting
enzyme and AD [4].
Angiotensin-converting enzyme (ACE) is an endopeptidase
that consists of two catalytic domains and is normally
expressed by endothelial, epithelial and neuronal cells [5]. It
exists in both membrane-bound (ACE) and soluble (sACE)
forms, the latter is produced by the action of an as yet uniden-
tified zinc metalloprotease (‘ACE secretase’) which cleaves
mature, membrane-bound ACE at a juxtamembranous extra-
cellular domain to release the large extracellular part of the
enzyme [6,7]. The traditional view of the function of ACE
relates to the renin-angiotensin system (RAS) pathway, within
which ACE catalyzes the formation of the vasoconstrictor
octapeptide angiotensin II (Ang II) from its non-vasoactive
precursor angiotensin I (Ang I) and is also responsible for
cleavage and inactivation of the vasodilator bradykinin [8].
The net result is vasopressor activity, which can be blocked
by ACE inhibitors – a standard treatment for hypertension
[9]. More recently ACE has been shown to cleave amyloid-b
(Ab), the accumulation of which is central to the pathogenesis
of Alzheimer’s disease (AD) and cerebral amyloid angiopathy
(CAA). ACE-mediated cleavage of Ab has been demonstrated
in vitro [10], ex vivo [11] and in some [12] but not in all [13]
recently studied animal models of AD.
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published studies of ACE protein levels and enzyme activity
in human brain tissue, ACE was found to be elevated in AD
[13].
Several studies have shown ACE to be capable of degrading
Ab in vitro. Variations in ACE were associated with differ-
ences in CSF Ab level [22], and some animal data suggested
that Ab level was increased by administration of ACE inhibi-
tors. It is not well documented whether ACE inhibitor use in
humans influences Ab accumulation. However, some studies
revealed a correlation between ACE inhibitor administration
and LOAD, where about 39.53% of the LOAD patients were
administering ACE inhibitors while only 18.6% of controls did
[2].
We aimed to investigate whether there is a correlation
between polymorphisms of the ACE I/D locus gene and AD
in Egyptian patients. We also aimed to determine whether
there is a difference in ACE activity in the plasma of clinically
diagnosed AD patients.
2. Materials and methods
2.1. *Patients and controls
This study was conducted in the Medical Research Center at
Ain-Shams University hospitals, on a total of 84 dementia
patients diagnosed as having Alzheimer’s disease from the
Geriatric Department at Ain-Shams University Hospitals,
(45 males and 39 females aged 65 ± 7 years) and 86 individu-
als as non dementia controls, (44 males and 42 females aged
63 ± 6 years).
All subjects included in this study were subjected to full his-
tory taking, thorough clinical examination, and ACE I/D
polymorphism typing and ACE plasma level was measured
for AD patients.
The work was done after taking acceptance of all patients
and controls to share in the study as well as acceptance of eth-
ics committee of the University. The works have been carried
out in accordance with the code of Ethics of the World Med-
ical Association (Declaration of Helsinki) for experiments
involving humans.
2.2. *ACE I/D genotype detection
DNA was extracted from whole blood using a QIAamp Blood
mini-prep Kit (QIAGEN, Germany) according to manufac-
turer’s instructions.
Genomic DNA (300 ng) was amplified in a final volume of
50 ll, containing 10 mM TRIS pH 8.3, 50 mM KCl, 1.5 mM
MgCl2, 200 mM each dNTP, 1 lM of each primer and 2U
Taq polymerase (all reagents from MBI Fermentas, St.
Leon-Rot, Germany). Details of ACE D/I genotype determi-
nation have been described according to Lindpaintner et al.
[25]. The differentiation between D and I alleles in heterozy-
gous samples was done according to the method described
by Lindpaintner et al., and originally described by Shanmu-
gam et al. [26].
We used an optimized primer pair to amplify the D and I
alleles, resulting in 319-bp and 597-bp amplicons, respectively
(hace3s, 50 GCCCTGCAGGTGTCTGCAGCATGT30;
hace3as, 50GGATGGCTCTCCCCGCCTTGTCTC30). The
thermocycling procedure (9700 apparatus, Applied Biosystem,
USA.) consisted of denaturation at 94 C for 30 s, annealing at
56 C for 45 s, and extension at 72 C for 2 min, repeated for
35 cycles, followed by a final extension at 72 C for 7 min.
After the addition of 5 ll of a glycerol-based loading buffer
(bromophenol blue), 7 ll of the mixture was loaded onto a
1.5 percent submarine agarose slab (BIOMETRA, Germany)
containing 40 mM TRIS acetate, 2 mM EDTA, and 1 lg of
ethidium bromide per milliliter of solution and fractionated
according to size of 100 bp molecular weight marker (Fermen-
tas, St. Leon-Rot, Germany). The amplification products of
the D and I alleles were identified at 319-bp and 597-bp ampli-
cons, respectively by 300-nm ultraviolet transillumination as
distinct bands as shown in Fig. 1.
2.3. *ACE plasma activity assay
Blood for ACE plasma activity assay was collected from AD
patients only, into heparinized tubes and centrifuged and the
plasma was stored at 70 C until assay. To establish ACE
activity, a colorimetric method, using Fortress diagnostics kit
was adopted. Based on hydrolysis of furanacryloyl-L-phenyl-
alanylglycylglycine (FAPGG) to FAP and Glycylglycine and
was quantified by measuring the decrease in absorbance at
340 nm. (Fortress Diagnostics Limited, Unit 2C Antrim Tech-
nology Park, Antrim, BT41 1QS (United Kingdom).
2.4. Statistical analysis
Statistical analyses were carried out with SPSS 18.0 software
for Windows. Comparisons of the allele and genotype frequen-
cies between groups were assessed using X2 test analyses. The
95% confidence interval (CI) and Odds ratio (OR) were used
to estimate the risk for developing AD. The criterion for signif-
icance was set at p< 0.05 for all the tests.
Figure 1 Shows a 2% Agarose gel analysis of amplified
Polymerase chain reaction (PCR) to detect ACE insertion/deletion
polymorphisms showing: Lane 1: 100 bp ladder Marker. Lane 2:
heterozygous (I/D), Lanes 3, 5, 6 and 7 are homozygous for the
deletion allele (D/D). Lanes 4 and 8 are homozygous for the
insertion allele (I/I).
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3. Results
The ACE genotype and allele distribution are shown in Tables
1 and 2. According to our data there was a significant differ-
ence in allele and genotype frequency between AD patients
and controls.
It was observed that the frequency of DD genotype was low
(26%) in AD patients as compared to controls (85%) with
p< 0.05 while there was no statistically significant difference
between the AD group and the control group in ID heterozy-
gote frequency which was 10% in controls and 13% in the AD
group with p= 0.427. On the other hand, the II genotype had
a higher frequency in the AD group (60%) as compared to
controls (5%) with a statistically significant difference
p< 0.01.
The ACE allele frequencies in both groups shown in
Table 2, revealed that the D allele was found to be predomi-
nant among normal subjects (95%) while the I allele was pre-
dominant among the AD group (74%).
The I allele distribution in AD cases and controls was 74%
vs. 15%, and the I/I genotype frequency was 60% vs. 5%,
respectively. They both reached a statistical significance range
at p< 0.01.
No significant relation was observed between the ACE gene
polymorphism when compared with age and gender of the
studied population (data not shown).
Furthermore, plasma level of ACE in patients with I/I
genotype was lower than those with D/D or D/I genotypes,
but was not statistically significant as shown in Table 3.
4. Discussion
The indel polymorphism, consisting of the presence or absence
of a 287-bp DNA fragment, has been considered the bio-
marker of AD, although its validity varies with race. The
meta-analyses addressing the relation-ship between ACE indel
polymorphism and AD have shown that I allele and I/D geno-
type are associated with an increased risk of AD, and D/D
genotype with reduced risk of AD [27,28]. However, these find-
ings are not consistent with different subgroups of Caucasians,
north Europeans and south Caucasians (Mediterranean and
Middle East) and within Asians [22]. Another published stud-
ies reported no association [29] or association with a particular
age group in Caucasians-Americans [30].
Even in Asians, such associations between ACE indel poly-
morphism and AD were not consistently detected among Jap-
anese and Taiwanese. For Japanese, the ACE I homozygote
was associated with the increased prevalence of AD [31] which
is in accordance with our results; however the result could not
be duplicated, as another study found a significant ethnic differ-
ence of the genotype distribution, but failed to replicate the
positive association between the I allele and AD [32]. For Tai-
wanese, the D homozygote and D allele were significantly asso-
ciated with the increased prevalence of AD [33], which is
different from the results in the Japanese study and our study.
Nonetheless, the relationship between ACE and AD is con-
troversial. Several studies have implicated the ID polymor-
phism and risk of AD [34], while other studies failed to find
an association [35]. Moreover, the pattern of association has
been confusing, with some studies showing an association with
the I allele [36], while others with the D allele [37].
A possible biological explanation for an association
between ACE and AD is still unclear. The insertion allele
appears to reduce ACE expression, and DD homozygotes
and ID heterozygotes have more circulating ACE than II
homozygotes: 65%, and 31%, respectively. This increased
activity of the D allele may alter Ab deposition by a direct pro-
teolytic mechanism [38]. Several studies suggest that there may
be a relationship between cardiovascular lesions and the sever-
ity and progression of AD [39].
We found an association between ACE variants and AD,
where inheritance of the II genotype of the ACE gene was
associated with a higher risk of AD while inheritance of the
homozygous DD genotype was associated with a lower risk
for AD. The latter observation was confirmed in several
meta-analyses [22] and more recently in whole-genome associ-
ation studies [40].
Several studies have examined the association of ACE I/D
polymorphism and ACE plasma concentration and have deter-
mined that the D allele or D/D homozygote is associated with
increased plasma ACE level [41].
ACE inhibitors seem to provide protection of cognitive
function in AD patients. A clinical study has found that using
Table 1 Genotype frequencies at the ACE I/D locus in AD
and control groups.
AD Controls p-value Odds ratios (95% CI)
No. (%) No. (%)
DD (%) 22 (26%) 73(85%) <0.05* 1.24 (1.10–3.56)
ID (%) 11 (13%) 9 (10%) 0.427 0.36 (0.20–0.64)
II (%) 51 (60%) 4 (5%) <0.01* 3.18 (2.33–4.33)
* P< 0.05 is statistically significant.
Table 2 Allele frequencies at the ACE I/D locus in AD and
control groups.
AD Controls p Odds ratios (95% CI)
D allele (%) 33 (39%) 82 (95%) <0.05* 1.765 (1.268–4.185)
I allele (%) 62 (74%) 13 (15%) <0.01* 3.714 (1.311–10.523)
* p< 0.05 is statistically significant.
Table 3 Mean plasma ACE activity of different ACE genotypes in AD patients.
DD DI II X2 P-value
Plasma ACE activity (U/L) Mean ± SD 56.6 ± 13.7 45.3 ± 10.5 34.4 ± 11.7 1.178 0.333*
* p is insignificant.
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brain-penetrating ACE inhibitors could slow the deterioration
of cognitive function of these patients, because ACE inhibitors
may enhance the release of acetylcholine in human cortex slices
and increase cerebral blood perfusion and vasomotor reactiv-
ity [42,43].
In our study individuals carrying the ACE II ‘risk’ genotype
for AD had no statistically significant differences in plasma
ACE activity as compared to samples of heterozygous or
homozygous of the ‘protective’ D allele with intermediate risk.
It is still unclear whether ACE indel polymorphism can be a
biomarker of AD. However, it is important to clarify this point
not only for the biomarker itself, but also for the emerging
alternative therapy provided by the ACE protein. They appear
to conflict over the point that using ACE inhibitors can slow
the decline of cognitive function of AD patients and in the
in vitro study, ACE can directly degrade b-amyloid. The pos-
sible benefits of using ACE inhibitors to slow cognitive func-
tion may depend on the ACE genotype of the patient,
although this lacks definite evidence. These current conflicts
and possible benefits of using ACE inhibitors to AD should
be clarified in future research.
In conclusion, our present study support the hypothesis of
implication (I allele) of ACE in the development of AD. On the
other hand, we did not find significant difference in plasma
ACE activities when compared with different studied geno-
types in AD patients, indicating that measurements of periph-
eral ACE are not a reliable indicator of ACE brain activity in
AD patients.
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